Company Filing History:
Years Active: 2023-2024
Title: Innovations by James Novotny, Jr. in Cancer Treatment
Introduction
James Novotny, Jr. is a notable inventor based in Milford, NJ (US). He has made significant contributions to the field of cancer treatment, particularly in the development of methods targeting LAG-3 positive tumors. With a total of 2 patents, his work is paving the way for advancements in immunotherapy.
Latest Patents
One of his latest patents focuses on the treatment of LAG-3 positive tumors. The invention outlines a method for treating tumors in human patients by identifying those with LAG-3 positive tumors. The treatment involves administering a PD-1 pathway inhibitor, a combination of a PD-1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor. In certain cases, the method also includes identifying patients with LAG-3 positive PD-L1 positive tumors. The use of anti-LAG-3 antibodies and anti-PD-1 antibodies is emphasized, as these methods can enhance response rates to treatment.
Career Highlights
James Novotny, Jr. is currently associated with Bristol-Myers Squibb Company, where he continues to innovate in the field of cancer research. His work is instrumental in developing therapies that improve patient outcomes.
Collaborations
He collaborates with esteemed colleagues such as Nils Lonberg and Cyrus Hedvat, contributing to a dynamic research environment that fosters innovation.
Conclusion
James Novotny, Jr. is a prominent figure in cancer treatment innovation, with his patents reflecting a commitment to improving therapeutic strategies for patients. His contributions are vital in the ongoing battle against cancer.